Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Clin Breast Cancer. 2021 Aug;21(4):e462-e470. doi: 10.1016/j.clbc.2021.01.014. Epub 2021 Jan 23.
Accumulating studies have demonstrated that microRNAs (miRNAs) are involved in the progression of various cancers. This study aimed to investigate the potential clinical and functional role of miR-432 in breast cancer.
We evaluated the expression of miR-432 in 117 breast cancer samples and paired nontumor tissue samples, as well as 4 breast cancer cell lines using RT-qPCR analysis. Kaplan-Meier survival curve and multivariate Cox regression analysis were used to evaluate the prognostic significance of miR-432 in breast cancer patients. CCK-8 assay and Transwell assays were used to evaluate the biological function of miR-432 in the progression of breast cancer.
miR-432 was downregulated in breast cancer tissues and cell lines, and its exotic expression was associated with tumor size, lymph node metastasis, and TNM stage. In addition, breast cancer patients with low miR-432 expression exhibited a shorter overall survival outcome. Further experiments revealed that overexpression of miR-432 inhibited the cell proliferation, migration, and invasion of breast cancer cells, while knockdown of miR-432 promoted these cellular activities. AXL was a direct target of miR-432 in breast cancer cells.
The present study suggested that miR-432 may be a tumor suppressor in the progression of breast cancer through inhibiting cell proliferation, migration, and invasion by targeting AXL. And miR-432 might be a prognostic biomarker and therapeutic target for the treatment of breast cancer. This study provided a novel insight into breast cancer prognosis and treatment.
越来越多的研究表明 microRNAs（miRNAs）参与了多种癌症的进展。本研究旨在探讨 miR-432 在乳腺癌中的潜在临床和功能作用。
我们使用 RT-qPCR 分析评估了 117 例乳腺癌样本和配对非肿瘤组织样本以及 4 株乳腺癌细胞系中 miR-432 的表达。Kaplan-Meier 生存曲线和多变量 Cox 回归分析用于评估 miR-432 在乳腺癌患者中的预后意义。CCK-8 检测和 Transwell 检测用于评估 miR-432 在乳腺癌进展中的生物学功能。
miR-432 在乳腺癌组织和细胞系中下调，其异位表达与肿瘤大小、淋巴结转移和 TNM 分期相关。此外，miR-432 低表达的乳腺癌患者总生存期较短。进一步的实验表明，miR-432 的过表达抑制了乳腺癌细胞的增殖、迁移和侵袭，而 miR-432 的敲低则促进了这些细胞活动。AXL 是乳腺癌细胞中 miR-432 的直接靶标。
本研究表明，miR-432 可能通过靶向 AXL 抑制乳腺癌细胞的增殖、迁移和侵袭，从而成为乳腺癌进展中的肿瘤抑制因子。miR-432 可能是乳腺癌预后和治疗的一个有前途的生物标志物和治疗靶点。本研究为乳腺癌的预后和治疗提供了新的见解。
